A Pill for Sleep Apnea Could Be on the Horizon
Poor sleep can leave people feeling exhausted, irritable and unfocused during the day. And if left untreated, sleep apnea can increase the risk for serious conditions like high blood pressure, Type 2 diabetes, heart attack and stroke.
For decades, the primary treatment for sleep apnea has been continuous positive airway pressure (or CPAP). Before bed, those with the condition put on a face mask that is connected to a CPAP machine, which keeps the airway open by forcing air into it. The machines are effective, but many find them so noisy, cumbersome or uncomfortable that they end up abandoning them.
Now, a more appealing option may be on the way, according to a news release from Apnimed, a pharmaceutical company focused on treating sleep apnea. On Wednesday, the company announced a second round of positive Phase 3 clinical trial results for a first-of-its-kind oral pill that can be taken just before bedtime to help keep a person's airway open.
The full results have not yet been released, or published in a peer-reviewed journal. But the findings build on past, similarly positive conclusions from trials and studies. Sleep experts say that what they're seeing in reports so far makes them think the pill could be a game changer.
Dr. Phyllis Zee, a sleep doctor and researcher at Northwestern Medicine who was not involved with the trial, said that if approved, the drug could transform the lives of many. That includes not only those who can't tolerate CPAP machines, but also those who can't — or prefer not to — use other interventions, such as other types of oral devices or weight loss medications. (Excess weight is a risk factor for sleep apnea.)
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
22 minutes ago
- Bloomberg
NASA Acting Chief Duffy Issues Directive to Speed Up Moon Reactor Plans
NASA's acting administrator Sean Duffy plans to accelerate the construction of a nuclear reactor that could be used on the moon and alter the way NASA will partner with industry to replace the aging International Space Station. The plans, outlined in directives distributed inside NASA and seen by Bloomberg on Monday, mark the first major policy changes by Duffy after US President Donald Trump appointed him to the role as acting head of the space agency.
Yahoo
33 minutes ago
- Yahoo
Kaul joins multistate suit claiming Trump has sought to deter care of transgender youths
Wisconsin Attorney General Josh Kaul joined a multistate lawsuit Aug. 1 suing the Trump administration for "relentlessly, cruelly and unlawfully" targeting transgender people. The lawsuit, filed in the U.S. District Court for the District of Massachusetts, comes six months after Kaul vowed to pursue legal actions should the federal government attempt to impede funding for gender-affirming health care. Recent federal actions have sought to deter health care providers from treating transgender patients under the age of 19, despite states like Wisconsin having laws in place that allow for medically appropriate procedures. President Donald Trump's Jan. 28 order oversteps its authority, the lawsuit states, by intimidating providers through threats of civil and criminal prosecution. The lawsuit emphasizes the order not only "has no basis in law" but is unconstitutional. Ultimately, the lawsuit is requesting the court to block the administration's actions and cease enforcing the order. 'The Trump administration shouldn't be interfering with the provision of health care,' Kaul said in a press release last week. 'The administration should be respecting individual liberty and equal rights, not shamefully targeting transgender people.' Trump's directive, signed early in his second term, aims to strip funds from medical institutions that provide gender-affirming care, and would require federal health programs like Medicaid and TRICARE (for military families) to exclude coverage of gender-affirming surgeries and hormone treatments for young people by 2026. Gender-affirming medical care supports people whose gender identity is out of sync with the sex they were assigned at birth. Health care may include the use of hormones to delay puberty in adolescents, behavioral health counseling to support and promote the gender identity with which a person aligns, and hormone replacement therapy. In very rare cases for young people, it may involve surgery. Access to gender-affirming services has been associated with lower suicide risks for transgender people. Research has also shown that people encountering anti-transgender bias and a denial of services had more than double the prevalence of suicide attempts than those who didn't have such experiences, according to the Williams Institute. The attorneys general warn the administration's tactics have had a chilling effect on states' ability to provide gender-affirming services. Despite protective laws being on the books, health care providers have already scaled back the services they offer to transgender youth. Other gender clinics have shuttered services completely in an attempt to avoid civil or criminal investigations and actions. Joining Kaul in filing this lawsuit are the attorneys general of California, Connecticut, Delaware, Hawai'i, Illinois, Maine, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New Mexico, New York, Rhode Island, and the District of Columbia, as well as the Governor of Pennsylvania. Natalie Eilbert covers mental health issues for the Milwaukee Journal Sentinel. She welcomes story tips and feedback. You can reach her at neilbert@ or view her X (Twitter) profile at @natalie_eilbert. This article originally appeared on Milwaukee Journal Sentinel: Wisconsin AG Kaul joins suit claiming Trump deters transgender care Solve the daily Crossword
Yahoo
38 minutes ago
- Yahoo
Why Curaleaf Stock Popped by 15% on Monday
Key Points Good news benefiting the cannabis industry was beneficial for the company too. There were pot-positive developments on both the medical and political fronts. 10 stocks we like better than Curaleaf › Pardon the use of the adjective, but it was obvious on Monday that the market has high hopes for cannabis company Curaleaf (OTC: CURLF). Investors piled into the stock after some positive news developments affecting its industry hit the headlines. By the time the smoke had cleared, Curaleaf was left standing with a more than 15% gain in its stock price that day. This obliterated the 1.4% advance of the S&P 500 index. Drug of choice The first news item producing that buzz was research published by the influential American Medical Association (AMA). In its Journal of the American Medical Association, the AMA detailed research from a survey that evaluated a clutch of drugs for how they affected eating disorders. Of the numerous drugs tested, the Journal noted, cannabis and psychedelic compounds were the highest-rated for alleviating symptoms of eating disorders. On top of that, marijuana and the psychedelics LSD and psilocybin also performed well in terms of overall mental health. These contrasted with the generally weak showing of nicotine and alcohol, which the Journal said were frequently ranked by the respondents as being the most harmful substances. Marijuana is legally sold as a medicine to qualifying patients in most U.S. states. If the drug can indeed treat eating disorders, this could dramatically enhance its appeal as a medical drug. Pot lobbying Another item of interest was Federal Election Commission (FEC) filings cited by several media outlets revealing that a pot industry-supported political action committee (PAC) made a meaty donation to President Trump's MAGA Inc. This is a so-called "super PAC" entitled to raise unlimited amounts of money to support political figures. The American Rights and Reform PAC, fueled by donations from marijuana companies, has donated $1 million to MAGA Inc. Although that's relatively small given the over $177 million the latter absorbed in the first six months of the year, this does indicate that the weed industry is actively lobbying influential people in U.S. politics. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Popped by 15% on Monday was originally published by The Motley Fool Sign in to access your portfolio
